AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21216311
Drug: MVA-HIV (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA-HIV (high dose 10^9 pfu/2 ml)
Trial: 21216475
Drug: Various medications
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various medications administered in level 3
Trial: 21217520
Drug: Granulocyte-macrophage colony-stimulating
RxNorm normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF)-based immunotherapy
Trial: 21219411
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg intravenous sildenafil bolus
Trial: 21219411
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oral sildenafil tablet
Trial: 21219434
Drug: Always used
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Always used injection-meal interval (Type 1 diabetes); n=39, age 58 years, duration of diabetes 21.1 years, BMI 28.7 kg/m², HbA(1c) 7.50%/58 mmol/mol
Trial: 21219434
Drug: Always used
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Always used injection-meal interval (Type 2 diabetes); n=124, age 65 years, duration of diabetes 13.8 years, BMI 32.6 kg/m², HbA(1c) 7.31%/56 mmol/mol
Trial: 21220472
Drug: CBP501 alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBP501 alone (0.9 mg/m(2), D1/D8/D15, q4w)
Trial: 21220472
Drug: CBP501 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBP501 in combination with cisplatin (3.6 mg/m(2) CBP501, 50 mg/m(2) cisplatin, both on D1, q3w)
Trial: 21220472
Drug: CBP501/cisplatin combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBP501/cisplatin combination
Trial: 21220675
Drug: Cholinesterase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinesterase inhibitors (ChEIs) and memantine hydrochloride
Trial: 21220675
Drug: Cholinesterase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinesterase inhibitors (ChEIs) only
Trial: 21224368
Drug: CT-322 (BMS-844203)
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CT-322 (BMS-844203) 2 mg/kg i.v. weekly (qw) or biweekly (q2w)
Trial: 21224368
Drug: CT-322 (BMS-844203)
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CT-322 (BMS-844203) 0.1 to 3.0 mg/kg i.v. qw or q2w
Trial: 21224368
Drug: CT-322 (BMS-844203)
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CT-322 (BMS-844203) 3.0 mg/kg i.v. qw or q2w
Trial: 21226540
Drug: Correlation between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation between omega-3 index and fasting insulin level
Trial: 21226927
Drug: Clopidogrel (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (600 mg loading dose, followed by 75 mg daily)
Trial: 21226927
Drug: Aspirin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (500 mg loading dose, followed by 100 mg daily)
Trial: 21226927
Drug: Structured therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured therapy plan based on a 'test and treat' strategy
Trial: 21232745
Drug: MMP-1 G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMP-1 G insertion
Trial: 21233271
Drug: Ataluren (PTC124)
DrugBank: Ataluren (DB05016)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Ataluren (PTC124) lower dose (4, 4 and 8 mg·kg(-1))
Trial: 21233271
Drug: Ataluren (PTC124)
DrugBank: Ataluren (DB05016)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Ataluren (PTC124) higher dose (10, 10 and 20 mg·kg(-1))
Trial: 21234288
Drug: Breast health
RxNorm normalized name: Ascorbic Acid/Bioflavonoid/Broccoli/Curcumin/Flaxseed/Genistein/Selenium 100 MG-50 MG-85 MG-300 MG-200 MG-10 MG-0.1 MG Oral Tablet [PROHERBS BREAST HEALTH]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast health supplement containing HMR lignan, indole-3-carbinol, calcium glucarate, milk thistle, Schisandra chinesis and stinging nettle for 28 days
Trial: 21239695
Drug: Bendamustine 90
RxNorm normalized name: bendamustine 90 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine 90 mg/m² days 1 and 4; Rituximab 375 mg/m² day 1; Bortezomib 1.3 mg/m² days 1, 4, 8, 11 (6 cycles of 28 days)
Trial: 21239695
Drug: Bendamustine, Bortezomib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine, Bortezomib, and Rituximab combination
Trial: 21239698
Drug: Flavopiridol (30-mg/m(2)
RxNorm normalized name: M
DrugBank: Alvocidib (DB03496)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavopiridol (30-mg/m(2) bolus, 60-mg/m(2) infusion)
Trial: 21239698
Drug: Flavopiridol (30-mg/m(2)
RxNorm normalized name: M
DrugBank: Alvocidib (DB03496)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavopiridol (30-mg/m(2) bolus, 70-mg/m(2) infusion)
Trial: 21242187
Drug: Re-induction therapy
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-induction therapy
Trial: 21242491
Drug: Tandutinib 500
RxNorm normalized name: Tandutinib
DrugBank: Tandutinib (DB05465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tandutinib 500 mg twice daily
Trial: 21242992
Drug: Sertraline (open-label
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (open-label treatment for 8 weeks)
Trial: 21244307
Drug: Ropinirole prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropinirole prolonged release (PR), maximum 24 mg/day
Trial: 21245420
Drug: Adjuvant trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant trastuzumab with chemotherapy
Trial: 21249218
Drug: Sodium nitrite
RxNorm normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium nitrite infusion (starting dose at 4.2 µg/kg/hr; maximal dose of 533.8 µg/kg/hr)
Trial: 21249218
Drug: Sodium nitrite
RxNorm normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium nitrite infusion at maximal tolerated dose
Trial: 21251631
Drug: Combination SYNTAX-PAMI
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination SYNTAX-PAMI score
Trial: 21251673
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg alfuzosin XL for 12 months
Trial: 21252240
Drug: Incretin effect
RxNorm normalized name: Secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Incretin effect measured over 6 days with three 4-h oral glucose tolerance tests (25, 75, and 125 g)
Trial: 21252240
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose tolerance tests with increasing glucose loads
Trial: 21252240
Drug: Incretin hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Incretin hormone responses
Trial: 21253319
Drug: Overall chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall chemotherapy (FOLFOX and XELOX)
Trial: 21253319
Drug: No prior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prior chemotherapy
Trial: 21255766
Drug: Any antidepressant
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any antidepressant
Trial: 21255766
Drug: Guideline-level antidepressant
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-level antidepressant dose and duration
Trial: 21255766
Drug: Serotonergic antidepressants
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonergic antidepressants and individual psychotherapy
Trial: 21256189
Drug: Ag85B-ESAT-6 combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ag85B-ESAT-6 combined with the adjuvant IC31(®), administered at 0 and 2 months
Trial: 21262916
Drug: Carboplatin/pemetrexed therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin/pemetrexed therapy
Trial: 21263104
Drug: Baseline macroalbuminuria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline macroalbuminuria treated with ACE inhibitor/ARB
Trial: 21267044
Drug: 24-hour intravenous
RxNorm normalized name: 24 Hour Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour intravenous patient-controlled analgesia (IV-PCA) with oxymorphone
Trial: 21267531
Drug: Preoperative chemoradiation
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemoradiation with capecitabine (825 mg/m² twice a day on radiotherapy days; weeks 1-4) and oxaliplatin (50 mg/m² intravenously on days 1, 8, 15, and 22) with radiotherapy (total dose 45 Gy)
Trial: 21267960
Drug: Converting enzyme
RxNorm normalized name: Prohormone converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Converting enzyme inhibitors (88%)
Trial: 21267960
Drug: Beta-blockers (77%)
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (77%)
Trial: 21267960
Drug: Both converting
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both converting enzyme inhibitors and beta-blockers (60%)
Trial: 21273144
Drug: Second-generation drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation drug-eluting balloons (DEB) including SeQuent Please, In.Pact Falcon, New Dior, Pantera Lux
Trial: 21273144
Drug: Second-generation drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation drug-eluting balloons (DEB)
Trial: 21273493
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro with rHuPH20
Trial: 21273493
Drug: Regular human
RxNorm normalized name: insulin regular human recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular human insulin (RHI) with rHuPH20
Trial: 21273493
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro without rHuPH20
Trial: 21273493
Drug: Regular human
RxNorm normalized name: insulin regular human recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular human insulin (RHI) without rHuPH20
Trial: 21273938
Drug: Trivalent, inactivated
RxNorm normalized name: poliomyelitis, trivalent, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent, inactivated influenza vaccine (TIV), 2 doses
Trial: 21274359
Drug: Multimodal lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal lifestyle intervention (11 group sessions and weekly fitness training for 5 months)
Trial: 21274364
Drug: Rivastigmine transdermal
RxNorm normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine transdermal patches (4.6 mg/24 h)
Trial: 21274364
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 to 10 mg/d)
Trial: 21277691
Drug: High-energy focused
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-energy focused extracorporeal shockwave therapy
Trial: 21281234
Drug: GM-ELISA- and
RxNorm normalized name: metformin and ertugliflozin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-ELISA- and Aspergillus PCR-driven antifungal therapy
Trial: 21281234
Drug: Standard fever-driven
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard fever-driven empiric antifungal treatment strategy
Trial: 21282484
Drug: Subgroup analysis
RxNorm normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgroup analysis of patients with idiopathic PAH and those with PAH associated with drugs and toxins
Trial: 21284479
Drug: Continuous glucose
RxNorm normalized name: sub-q infusion pump w/continuous glucose monitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous glucose monitoring with microdialysis-based subcutaneous glucose monitoring system
Trial: 21288612
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein supplement (WPS) 60 g/day for 4 weeks
Trial: 21289257
Drug: Oral water
RxNorm normalized name: Oral Wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral water load
Trial: 21289257
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 3% saline
Trial: 21289369
Drug: Sunitinib (second
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (second line treatment)
Trial: 21293986
Drug: Hard drug
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hard drug use (cocaine, amphetamines, or heroin)
Trial: 21296274
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) as salvage treatment after prostatic radiotherapy
Trial: 21296824
Drug: Reading Practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reading Practice with Sequential Presentation of Lexical Information (module 3)
Trial: 21299393
Drug: BD GGBP
RxNorm normalized name: BD-111
DrugBank: BD-111 (DB18247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BD GGBP sensor (intradermal placement)
Trial: 21299393
Drug: BD GGBP
RxNorm normalized name: BD-111
DrugBank: BD-111 (DB18247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BD GGBP sensor (subcutaneous placement)
Trial: 21300307
Drug: Baroreflex activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baroreflex activation therapy (BAT) using an implanted device (Rheos)
Trial: 21300566
Drug: Adjuvanted HIV-1
RxNorm normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted HIV-1 vaccine candidate
Trial: 21300924
Drug: Oral vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral vorinostat (200 mg twice daily on days 1-14 of a 21-day cycle)
Trial: 21304070
Drug: Ultrasmall superparamagnetic
RxNorm normalized name: Ultrasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasmall superparamagnetic particles of iron oxide (USPIO) administered before and 24 to 36 hours after MRI imaging
Trial: 21304982
Drug: MF59-adjuvanted pH1N1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted pH1N1 vaccine (Focetria®, Novartis) administered twice
Trial: 21308151
Drug: Givinostat (ITF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Givinostat (ITF 2357), an orally active HDAC inhibitor, administered for 12 weeks.
Trial: 21308151
Drug: Control not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control not specified, but implied comparison to standard treatments like methotrexate and anticytokines.
Trial: 21310866
Drug: Oral supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplementation with pyridoxine hydrochloride (40 mg/d) for 1 month
Trial: 21311383
Drug: Intravenous Magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Magnesium Sulphate
Trial: 21311694
Drug: Bone marrow
RxNorm normalized name: bone marrow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow mononuclear cells (BMMC) infusion after granulocyte colony-stimulating factor administration.
Trial: 21311694
Drug: BMMC cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMMC cell therapy
Trial: 21320979
Drug: anti-inflammatory treatment
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-inflammatory treatment
Trial: 21321062
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplementation (1 mg/d) for 8 weeks
Trial: 21321062
Drug: Low folate
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low folate diet for 12 weeks followed by folic acid repletion (1 mg/d) for 4 weeks
Trial: 21324375
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of AS03-adjuvanted H1N1 influenza vaccine
Trial: 21324375
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of AS03-adjuvanted H1N1 influenza vaccine
Trial: 21325343
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D deficiency (25[OH]D < 20 ng/mL)
Trial: 21325343
Drug: Increases in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increases in 25(OH)D to greater than or equal to 20 ng/mL
Trial: 21328719
Drug: Haloperidol (first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (first generation antipsychotic)
Trial: 21328719
Drug: Olanzapine (second
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (second generation antipsychotic)
Trial: 21329725
Drug: Tenofovir discontinuation
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tenofovir discontinuation
Trial: 21334595
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg ranibizumab injected monthly for one year
Trial: 21338641
Drug: Sorafenib (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (800 mg/d) plus metronomic tegafur/uracil (250 mg/m(2)/d)
Trial: 21338641
Drug: K(trans) change
RxNorm normalized name: Effer-K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K(trans) change after treatment
Trial: 21345726
Drug: Temsirolimus (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus (25 mg) and Bortezomib (1.6 mg/m2)
Trial: 21349999
Drug: Brivanib (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivanib (800 mg orally once daily)
Trial: 21352516
Drug: Web-enabled mobile
RxNorm normalized name: Enablex
DrugBank: Darifenacin (DB00496)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Web-enabled mobile phone intervention with daily online entries and individualized written feedback
Trial: 21352601
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg orally administered AS (artesunate)
Trial: 21355002
Drug: Belotecan (CKD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belotecan (CKD 602) at 0.5 mg/m(2)/day for 5 consecutive days every 3-week cycle
Trial: 21355077
Drug: Langerhans cell
RxNorm normalized name: Allogeneic human pancreatic islets of Langerhans
DrugBank: Allogeneic human pancreatic islets of Langerhans (DB18651)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Langerhans cell (LC) vaccines
Trial: 21355077
Drug: monocyte-derived dendritic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: monocyte-derived dendritic cell (moDC) vaccines
Trial: 21355087
Drug: Doxorubicin 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 25 mg/m(2), vinblastine 6 mg/m(2), and gemcitabine 800 mg/m(2) (1000 mg/m(2) in first 6) on days 1 and 15 every 28 days for 6 cycles
Trial: 21355097
Drug: Romidepsin (depsipeptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romidepsin (depsipeptide or FK228), a histone deacetylase inhibitor
Trial: 21355725
Drug: Insulin pump
RxNorm normalized name: insulin pump syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin pump therapy (Animas(®) 2020, Animas Corp.) for 16 weeks
Trial: 21356058
Drug: Other gastrointestinal
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR OTHER GASTROINTESTINAL DISEASES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other gastrointestinal drugs (except PPIs)
Trial: 21356079
Drug: Canakinumab 2
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Canakinumab 2 mg/kg subcutaneously (s.c.) for patients with body weight ≤ 40 kg or 150 mg s.c. for patients with body weight > 40 kg.
Trial: 21356124
Drug: 15-deoxyspergualin (DSG)
RxNorm normalized name: Deoxyspergualin
DrugBank: Deoxyspergualin (DB12991)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-deoxyspergualin (DSG) 0.5 mg/kg normal body weight/day, injected subcutaneously for 14 days, followed by a break of one week, repeated to a maximum of nine times.
Trial: 21356124
Drug: 15-deoxyspergualin (DSG)
RxNorm normalized name: Deoxyspergualin
DrugBank: Deoxyspergualin (DB12991)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-deoxyspergualin (DSG) treatment in 12 patients who completed all nine cycles.
Trial: 21356124
Drug: 15-deoxyspergualin (DSG)
RxNorm normalized name: Deoxyspergualin
DrugBank: Deoxyspergualin (DB12991)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-deoxyspergualin (DSG) treatment in 20 patients.
Trial: 21358295
Drug: Capecitabine (1,250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (1,250 mg/m² twice daily for 14 days, followed by 14 days of rest)
Trial: 21358415
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of left ventricular hypertrophy by Cornell product (1 year) or UACR (1 year) at least 1 mmol/l
Trial: 21359193
Drug: Iodine deficiency
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine deficiency (mean urinary iodine excretion, 49.8 µg/L)